L7 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1997:784151 CAPLUS
DOCUMENT NUMBER: 128:53279
TITLE: Transdermal patch with good skin compatibility and storage stability
INVENTOR(S): Hirano, Munehiko; Maki, Masayoshi
PATENT ASSIGNEE(S): Hisamitsu Pharmaceutical Co., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 17 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 09315957	A2	19971209	JP 1996-171579	19960528

PRIORITY APPLN. INFO.: JP 1996-171579 19960528

AB The preparation at least contains (A) a drug-impermeable backing layer, (B) a drug-storing layer, and (C) a drug-releasing layer comprising a drug-permeable film and a pressure-sensitive adhesive layer. The drug may be follicle hormones and/or progestins for hormone replacement therapy. A release liner was coated with an adhesive composition containing **styrene-isoprene-styrene** block copolymer, an acrylic adhesive, liquid paraffin, an alicyclic saturated hydrocarbon resin tackifier, polyisobutylene, and dibutylhydroxytoluene, and covered with a porous sheet. Subsequently a composition containing estradiol was poured onto the side of the porous sheet, and the area surrounding the drug composition was heat-sealed with a backing material to give a transdermal patch. Application of the patch to arm for 72 h caused no erythema.

10030015blessing

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN 50-28-2 REGISTRY
CN Estra-1,3,5(10)-triene-3,17-diol (17β)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN **Estradiol (8CI)**
OTHER NAMES:
CN (+)-3,17β-Estradiol
CN β-Estradiol
CN 13β-Methyl-1,3,5(10)-gonatriene-3,17β-ol
CN 17β-Estradiol
CN 17β-Oestradiol
CN 3,17-Epidihydroxyestratriene
CN 3,17β-Dihydroxyestra-1,3,5(10)-triene
CN 3,17β-Estradiol
CN Aerodiol
CN Altrad
CN Aquadiol
CN Bardiol
CN Beta-estradiol
CN Climaderm
CN Climara
CN Compudose
CN Compudose 200
CN Compudose 365
CN Corpagen
CN Dermestril
CN Dihydrofollicular hormone
CN Dihydrofolliculin
CN Dihydromenformon
CN Dihydrotheelin
CN Dihydroxyestrin
CN Dimenformon
CN Diogyn
CN Diogynets
CN Divigel
CN E 2
CN Encore
CN Epiestriol 50
CN Estra-1,3,5(10)-triene-3,17-diol, (17β)-
CN Estra-1,3,5(10)-triene-3,17β-diol
CN Estrace
CN Estraderm
CN Estraderm TTS
CN Estraderm TTS 100
CN Estraderm TTS 50
CN Estradot
CN Estraldine
CN Estring Vaginal Ring
CN Estroclim
CN Estroclim 50
CN Estrogel
CN Estrovite
CN Evorel
CN Femanest
CN Femestral
ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for

blessing

10030015blessing

DISPLAY
FS STEREOSEARCH
MF C18 H24 O2
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DIOGENES, DRUGU, EMBASE, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH, IMSDRUGNEWS, IMSRESEARCH, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PHAR, PIRA, PROMT, PROUSDDR, PS, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, ULIDAT, USAN, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: EINECS**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)
DT.CA CAplus document type: Book; Conference; Dissertation; Journal; Patent; Report
RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); MSC (Miscellaneous); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)
RLD.P Roles for non-specific derivatives from patents: ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)
RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); MSC (Miscellaneous); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)
RLD.NP Roles for non-specific derivatives from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

52115 REFERENCES IN FILE CA (1907 TO DATE)
869 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
52179 REFERENCES IN FILE CAPLUS (1907 TO DATE)
12 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

blessing

10030015blessing

blessing

10030015blessing

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN 68-22-4 REGISTRY
CN 19-Norpregn-4-en-20-yn-3-one, 17-hydroxy-, (17α)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 19-Nor-17α-pregn-4-en-20-yn-3-one, 17-hydroxy- (7CI, 8CI)
OTHER NAMES:
CN (17α)-17-Hydroxy-19-Norpregn-4-en-20-yn-3-one
CN 17-Hydroxy-19-nor-17α-pregn-4-en-20 yn-3-one
CN 17α-Ethinyl-17β-hydroxy-Δ4-estren-3-one
CN 17α-Ethinyl-19-nortestosterone
CN 17α-Ethinylestr-4-en-17β-ol-3-one
CN 17α-Ethynyl-17-hydroxy-4-estrene-3-one
CN 17α-Ethynyl-17-hydroxyest-4-en-3-one
CN 17α-Ethynyl-17-hydroxyestr-4-en-3-one
CN 17α-Ethynyl-17β-hydroxy-19-norandrost-4-en-3-one
CN 17α-Ethynyl-17β-hydroxyestr-4-en-3-one
CN 17α-Ethynyl-19-nor-androst-4-en-17β-ol-3-one
CN 17α-Ethynyl-19-nortestosterone
CN 17α-Ethynyl-3-oxo-4-estren-17β-ol
CN 17β-Hydroxy-17α-ethynylestr-4-en-3-one
CN 19-Nor-17α-ethynyl-17β-hydroxy-4-androsten-3-one
CN 19-Nor-17α-ethynylandrosten-17β-ol-3-one
CN 19-Nor-17α-ethynyltestosterone
CN 19-Norandrost-4-en-3-one, 17α-ethynyl-17β-hydroxy-
CN 19-Nortestosterone, 17-ethynyl-
CN Anovule
CN Conludaf
CN Conludag
CN Estr-4-ene-17α-ethynyl-17β-ol-3-one
CN Ethinylnortestosterone
CN Ethynylnortestosterone
CN Gestest
CN Menzol
CN Micronett
CN Micronor
CN Micronovum
CN Mini-Pe
CN Mini-pill
CN Nor-QD
CN Noralutin
CN Norcolut
CN Norethindrone
CN Norethisteron
CN **Norethisterone**
CN Norethynodrone
CN Norfor
CN Norgestin
CN Norluten
CN Norlutin
CN Norluton
CN Normapause
CN Norpregneninolone
CN NSC 9564
CN Primolut N
CN Proluteasi

blessing

10030015blessing

ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for DISPLAY
FS STEREOSEARCH
MF C20 H26 O2
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DIOGENES, DRUGU, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH, IPA, MEDLINE, MRCK*, MSDS-OHS, NIOSHTIC, PHAR, PIRA, PROMT, PS, RTECS*, SPECINFO, TOXCENTER, ULIDAT, USAN, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: EINECS**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)
DT.CA CAplus document type: Book; Conference; Dissertation; Journal; Patent; Report
RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)
RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); MSC (Miscellaneous); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)
RLD.NP Roles for non-specific derivatives from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2248 REFERENCES IN FILE CA (1907 TO DATE)
66 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
2251 REFERENCES IN FILE CAPLUS (1907 TO DATE)
7 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

blessing

10030015blessing

L7 ANSWER 1 OF 10 USPATFULL on STN
ACCESSION NUMBER: 2004:51925 USPATFULL
TITLE: Compositions for external preparations
INVENTOR(S): Maki, Masayoshi, Tashirodaikan-machi, Tosu-shi, JAPAN
Ikeura, Yasuhiro, Tashirodaikan-machi, Tosu-shi, JAPAN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004039356	A1	20040226
APPLICATION INFO.:	US 2003-399294	A1	20030414 (10)
	WO 2001-JP7632		20010904

	NUMBER	DATE
PRIORITY INFORMATION:	JP 2000-315179	20001016

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: EDWARDS & ANGELL, LLP, P.O. BOX 9169, BOSTON, MA, 02209
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
LINE COUNT: 563
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB It is intended to provide compositions for external preparations (in particular, adhesive preparations) which are excellent in the skin permeability of the active ingredient, make it possible to give a compact preparation size and exert relieved skin irritation in percutaneous preparations, etc. to be used in, for example, hormone substitution therapy. Namely, compositions for external preparation which contain a vegetable oil and polyvinyl pyrrolidone as a sorbefacient and/or a dissolution aid; and adhesive preparations containing these compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 2 OF 10 USPATFULL on STN
ACCESSION NUMBER: 2003:329862 USPATFULL
TITLE: Enhanced drug delivery in transdermal systems
INVENTOR(S): Houze, David, Coconut Grove, FL, UNITED STATES
Nguyen, Viet, Miami, FL, UNITED STATES
PATENT ASSIGNEE(S): Noven Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003232073	A1	20031218
APPLICATION INFO.:	US 2002-330281	A1	20021230 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. WO 2002-US16579, filed on 18 Jun 2002, PENDING
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FOLEY AND LARDNER, SUITE 500, 3000 K STREET NW, WASHINGTON, DC, 20007
NUMBER OF CLAIMS: 52
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Page(s)
LINE COUNT: 1399
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

blessing

10030015blessing

AB A composition for transdermal administration resulting from an admixture includes: a therapeutically effective amount of a drug that includes a parent drug and a prodrug; and and a pharmaceutically acceptable carrier, wherein the parent drug and prodrug are individually present in an amount sufficient for a pharmacological effect. In a preferred embodiment, the admixture includes: a therapeutically effective amount of a pharmaceutically active agent that includes a corresponding steroid and a steroid derivative; and a carrier for the pharmaceutically active agent. The steroid and the corresponding steroid derivative are present in a weight ratio of 10:1 to 1:10 steroid: corresponding steroid derivative. In a preferred embodiment ratio is 6:1 to 1:6. In a preferred embodiment, the corresponding steroid derivative is a steroid ester. In another preferred embodiment, the carrier is a polymer that includes a pressure-sensitive adhesive. In another preferred embodiment, the parent drug is an ACE inhibitor such as ramipril and the prodrug is an ACE inhibitor prodrug such as ramipril ethyl and/or methyl ester.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 3 OF 10 USPATFULL on STN
ACCESSION NUMBER: 2003:219325 USPATFULL
TITLE: Enhanced drug delivery in transdermal systems
INVENTOR(S): Houze, David, Coconut Grove, FL, UNITED STATES
PATENT ASSIGNEE(S): Noven Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003152615	A1	20030814
APPLICATION INFO.:	US 2002-330361	A1	20021230 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-948107, filed on 7 Sep 2001, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-298381P	20010618 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FOLEY AND LARDNER, SUITE 500, 3000 K STREET NW, WASHINGTON, DC, 20007
NUMBER OF CLAIMS: 31
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 825
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A composition for transdermal administration resulting from an admixture includes: a therapeutically effective amount of a pharmaceutically active agent that includes a corresponding steroid and a steroid derivative; and a carrier for the pharmaceutically active agent. The steroid and the corresponding steroid derivative are present in a weight ratio of 10:1 to 1:10 steroid: corresponding steroid derivative. In a preferred embodiment ratio is 6:1 to 1:6. In a preferred embodiment, the corresponding steroid derivative is a steroid ester. In another preferred embodiment, the carrier is a polymer that includes a pressure-sensitive adhesive.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

blessing

10030015blessing

L7 ANSWER 4 OF 10 USPATFULL on STN
ACCESSION NUMBER: 2003:219324 USPATFULL
TITLE: Enhanced drug delivery in transdermal systems
INVENTOR(S): Houze, David, Coconut Grove, FL, UNITED STATES
PATENT ASSIGNEE(S): Noven Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003152614	A1	20030814
APPLICATION INFO.:	US 2002-330360	A1	20021230 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2001-948107, filed on 7 Sep 2001, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-298381P	20010618 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FOLEY AND LARDNER, SUITE 500, 3000 K STREET NW, WASHINGTON, DC, 20007
NUMBER OF CLAIMS: 31
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 825
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A composition for transdermal administration resulting from an admixture includes: a therapeutically effective amount of a pharmaceutically active agent that includes a corresponding steroid and a steroid derivative; and a carrier for the pharmaceutically active agent. The steroid and the corresponding steroid derivative are present in a weight ratio of 10:1 to 1:10 steroid: corresponding steroid derivative. In a preferred embodiment ratio is 6:1 to 1:6. In a preferred embodiment, the corresponding steroid derivative is a steroid ester. In another preferred embodiment, the carrier is a polymer that includes a pressure-sensitive adhesive.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 5 OF 10 USPATFULL on STN
ACCESSION NUMBER: 2003:219323 USPATFULL
TITLE: Enhanced drug delivery in transdermal systems
INVENTOR(S): Houze, David, Coconut Grove, FL, UNITED STATES
PATENT ASSIGNEE(S): Noven Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003152613	A1	20030814
APPLICATION INFO.:	US 2002-330279	A1	20021230 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2001-948107, filed on 7 Sep 2001, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-298381P	20010618 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FOLEY AND LARDNER, SUITE 500, 3000 K STREET NW,

WASHINGTON, DC, 20007
NUMBER OF CLAIMS: 31
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 825
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A composition for transdermal administration resulting from an admixture includes: a therapeutically effective amount of a pharmaceutically active agent that includes a corresponding steroid and a steroid derivative; and a carrier for the pharmaceutically active agent. The steroid and the corresponding steroid derivative are present in a weight ratio of 10:1 to 1:10 steroid: corresponding steroid derivative. In a preferred embodiment ratio is 6:1 to 1:6. In a preferred embodiment, the corresponding steroid derivative is a steroid ester. In another preferred embodiment, the carrier is a polymer that includes a pressure-sensitive adhesive.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:31334 CAPLUS
DOCUMENT NUMBER: 134:91154
TITLE: Adhesive preparation for percutaneous absorption
INVENTOR(S): Maki, Masayoshi; Ikeura, Yasuhiro
PATENT ASSIGNEE(S): Hisamitsu Pharmaceutical Co., Inc., Japan
SOURCE: PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001001990	A1	20010111	WO 2000-JP4361	20000630
W: JP, KR, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1197212	A1	20020417	EP 2000-942427	20000630
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

PRIORITY APPLN. INFO.: JP 1999-187415 A 19990701
WO 2000-JP4361 W 20000630
AB The invention relates to an adhesive preparation for percutaneous absorption in which high drug permeability at a low drug concentration and satisfactory drug stability have been obtained by regulating the solubility of a drug in a base. The adhesive preparation comprises a base comprising a **styrene/isoprene/styrene** block copolymer and norethisterone contained in the base. Preferably, the drug is dissolved in the base in an amount of up to 2 weight% based on the whole base.
REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:260067 CAPLUS
DOCUMENT NUMBER: 132:270106
TITLE: Sorbefacients and preparations for percutaneous

10030015blessing

absorption containing the same
INVENTOR(S): Ikeura, Yasuhiro; Maki, Masayoshi
PATENT ASSIGNEE(S): Hisamitsu Pharmaceutical Co., Inc., Japan
SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000021566	A1	20000420	WO 1999-JP5670	19991014
W: AU, BR, CA, CN, ID, KR, NO, SG, US, VN				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
JP 2000119195	A2	20000425	JP 1998-291851	19981014
AU 9961229	A1	20000501	AU 1999-61229	19991014
EP 1121941	A1	20010808	EP 1999-947897	19991014
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

PRIORITY APPLN. INFO.: JP 1998-291851 A 19981014
WO 1999-JP5670 W 19991014

AB The invention relates to percutaneous sorbefacients comprising hexylene glycol and l-menthol, more particularly, percutaneous sorbefacients for female hormones or derivs. thereof; and prepns. for percutaneous absorption which comprise a **styrene/isoprene/styrene** block copolymer and/or polyisobutylene, a softener and a tackifier as the base components, hormones, in particular, follicle hormone and/or luteal hormone as the drug component and hexylene glycol and l-menthol as a sorbefacient.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1998:706123 CAPLUS
DOCUMENT NUMBER: 129:321217
TITLE: Base composition for percutaneous absorption and percutaneously absorbable preparation containing it
INVENTOR(S): Hirano, Munehiko; Maki, Masayoshi
PATENT ASSIGNEE(S): Hisamitsu Pharmaceutical Co., Inc., Japan
SOURCE: PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9846267	A1	19981022	WO 1998-JP1745	19980416
W: AU, BR, CA, CN, ID, KR, MX, NO, PL, SG, US, VN				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9868525	A1	19981111	AU 1998-68525	19980416
AU 723018	B2	20000817		
JP 11001441	A2	19990106	JP 1998-121664	19980416

blessing

10030015blessing

EP 976405	A1	20000202	EP 1998-914050		19980416
R: AT, CH, DE, ES, FR, GB, IT, LI, NL, SE, FI					
BR 9808594	A	20000523	BR 1998-8594		19980416
NO 9905032	A	19991015	NO 1999-5032		19991015
PRIORITY APPLN. INFO.:			JP 1997-115254	A	19970416
			WO 1998-JP1745	W	19980416

AB A base composition for percutaneous absorption comprises a **styrene/isoprene/styrene** block copolymer, softening agent, adhesive resin, and hexylene glycol. The base composition is useful for enhancement of percutaneous absorption of hormones such as estradiol in treatment of menopause and menstruation disorders.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 9 OF 10 USPATFULL on STN

ACCESSION NUMBER:	1998:124212 USPATFULL		
TITLE:	Percutaneously absorbable patch		
INVENTOR(S):	Hirano, Munehiko, Tsukuba, Japan		
	Shinmura, Miyuki, Tsukuba, Japan		
	Kojima, Masaki, Tsukuba, Japan		
PATENT ASSIGNEE(S):	Hisamitsu Pharmaceutical Co., Inc., Tosu, Japan (non-U.S. corporation)		

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5820878		19981013	
	WO 9615776		19960530	
APPLICATION INFO.:	US 1997-817878		19970428	(8)
	WO 1995-JP2336		19951115	
			19970428	PCT 371 date
			19970428	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1994-309762	19941118

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Page, Thurman K.
ASSISTANT EXAMINER:	Shelborne, Kathryne E.
LEGAL REPRESENTATIVE:	Kubovcik & Kubovcik
NUMBER OF CLAIMS:	7
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	6 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT:	665

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A percutaneously absorbable preparation-containing patch, wherein the preparation comprises: (1) a base comprising as essential ingredients a (A-B) n-A based elastomer wherein A is substantially a monovinyl-substituted aromatic compound polymer block, B is substantially a conjugated diolefin copolymer block, and n is an integer of 3-7, crotamiton, and a softening agent; and (2) at least two hormones, especially estrogen and luteal hormones, as active ingredients.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN

blessing

10030015blessing

ACCESSION NUMBER: 1997:784151 CAPLUS
DOCUMENT NUMBER: 128:53279
TITLE: Transdermal patch with good skin compatibility and storage stability
INVENTOR(S): Hirano, Munehiko; Maki, Masayoshi
PATENT ASSIGNEE(S): Hisamitsu Pharmaceutical Co., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 17 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 09315957	A2	19971209	JP 1996-171579	19960528

PRIORITY APPLN. INFO.: JP 1996-171579 19960528

AB The preparation at least contains (A) a drug-impermeable backing layer, (B) a drug-storing layer, and (C) a drug-releasing layer comprising a drug-permeable film and a pressure-sensitive adhesive layer. The drug may be follicle hormones and/or progestins for hormone replacement therapy. A release liner was coated with an adhesive composition containing **styrene-isoprene-styrene** block copolymer, an acrylic adhesive, liquid paraffin, an alicyclic saturated hydrocarbon resin tackifier, polyisobutylene, and dibutylhydroxytoluene, and covered with a porous sheet. Subsequently a composition containing estradiol was poured onto the side of the porous sheet, and the area surrounding the drug composition was heat-sealed with a backing material to give a transdermal patch. Application of the patch to arm for 72 h caused no erythema.

10030015blessing

```
 d his

     (FILE 'HOME' ENTERED AT 17:05:05 ON 11 JUN 2004)

     FILE 'REGISTRY' ENTERED AT 17:05:13 ON 11 JUN 2004
L1             1 S NORETHISTERONE/CN
L2             1 S ESTRADIOL/CN

     FILE 'CAPLUS, USPATFULL' ENTERED AT 17:06:20 ON 11 JUN 2004
L3          2497 S L1
L4         53372 S L2
L5          5582 S STYRENE(W)ISOPRENE(W)STYRENE
L6            10 S L3 AND L4 AND L5
L7            10 DUP REM L6 (0 DUPLICATES REMOVED)
```